Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 11
Submit an article Journal homepage
401
Views
62
CrossRef citations to date
0
Altmetric
Review

The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets

Francis Rodriguez Bambico McGill University, Neurobiological Psychiatry Unit, Department of Psychiatry, Research and Training Building, 1033 Pine Avenue West, Montréal Québec, H3A 1A1, Canada +1 514 398 1290; +1 514 398 4866; [email protected]
&
Gabriella Gobbi McGill University, Neurobiological Psychiatry Unit, Department of Psychiatry, Research and Training Building, 1033 Pine Avenue West, Montréal Québec, H3A 1A1, Canada +1 514 398 1290; +1 514 398 4866; [email protected]; Université de Montréal, Centre de Recherche Fernand Seguin, Department of Psychiatry, Montreal, Québec, Canada
Pages 1347-1366 | Published online: 14 Oct 2008

Bibliography

  • Burton R. The anatomy of melancholy, what it is, with all the kinds, causes, symptoms, prognostics and several cures of it. London: J Cuthell; 1862
  • Moreau (de Tours) JJ. Du hachisch et de l'alienation mentale, in Du hachisch et de l'alienation mental. Moreau Paris JJ, editor. Paris: Librairie de Fortin, Masson et Cie; 1845
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th edition. Washington, DC: American Psychiatric Association; 2000
  • Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62(6):617-27
  • Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7(2):137-51
  • Remick RA. Diagnosis and management of depression in primary care: a clinical update and review. CMAJ 2002;167:1253-60
  • Lecrubier Y. The burden of depression and anxiety in general medicine. J Clin Psychiatry 2001;62(Suppl):4-9
  • Parikh SV, Lam RW; CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence and health burden. Can J Psychiatry 2001;46(Suppl 1):S13-20
  • Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15(7):220-6
  • Trivedi MH, Rush AJ, Wisniewski SR, et al.; For the STAR*D StudyTeam. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
  • Shopsin B, Gershon S, Goldstein M, et al. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1975;1(2):239-49
  • Reader TA, Brière R, Grondin L, Ferron A. Effects of p-chlorophenylalanine on cortical monoamines and on the activity of noradrenergic neurons. Neurochem Res 1986;11(7):1025-35
  • Baraban JM, Aghajanian GK. Suppression of serotonergic neuronal firing by α-adrenoceptor antagonists: evidence against GABA mediation. Eur J Pharmacol 1980;66(4):287-94
  • Lesch KP. Gene–environment interaction and the genetics of depression. J Psychiatry Neurosci 2004;29:174-84
  • Rosa-Neto P, Diksic M, Okazawa H, et al. Measurement of brain regional α-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with with major depression. Arch Gen Psychiatry 2004;61(6):556-63
  • Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. 1999;46(2):212-20
  • Mann JJ, Huang YY, Underwood MD, et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000;57(8):729-38
  • Haddjeri N, Blier P, de Montigny C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 1998;51(3):255-66
  • Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides 2005;26(8):1383-93
  • Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005;97(3):317-36
  • Szabo ST, Blier P. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci 2001;13(11):2077-87
  • Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of vagus nerve stimulation in treatment-resistant depression. A systematic review. J Affect Disord 2008:110(1-2):1-15
  • Dremencov E, Gur E, Lerer B, Newman ME. Effects of chronic antidepressants and electroconvulsive shock on serotonergic neurotransmission in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(5):729-39
  • Haddjeri N, Blier P, de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 1998;18(23):10150-6
  • Aznar S, Knudsen GM. Serotonin induces a decrease of 5-HT(1A) immunoreactivity in organotypic hippocampal cultures. Neuroreport 2001;12(18):3909-12
  • Graeff FG, Guimarães FS, De Andrade, et al. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996;54(1):129-41
  • Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 2003;1003:250-72
  • Besson A, Haddjeri N, Blier, et al. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 2000;10(3):177-88
  • Shirayama Y, Chen AC, Nakagawa S, et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002;22(8):3251-61
  • Eisch AJ, Bolaños CA, de Wit J, et al. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol Psychiatry 2003;54(10):994-1005
  • Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000;20(24):9104-10
  • Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry 2000;157(1):115-8
  • Santarelli L, Saxe M, Gross C. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301(5634):805-9
  • Henn FA, Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon? Biol Psychiatry 2004;56(3):146-50
  • Castren E. Is mood chemistry? Nat Rev Neurosci 2005;6(3):241-6
  • Airan RD, Meltzer LA, Roy M, et al. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science 2007;317(5839):819-23
  • Mechoulam R, Devane WA, Breuer A, et al. A random walk through a cannabis field. Pharmacol Biochem Behav 1991;40(3):461-4
  • Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002;296(5568):678-82
  • Robbe D, Kopf M, Remaury A, et al. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 2002;99(12):8384-8
  • Carlson G, Wang Y, Alger BE. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci 2002;5(8):723-4
  • Berghuis P, Rajnicek AM, Morozov YM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 2007;316(5828):1212-6
  • Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4:873-84
  • Iversen L. Cannabis and the brain. Brain 2003;126:1252-70
  • Atha MJ, Blanchard S. Regular users – self-reported drug consumption patterns and attitudes to drugs among 1333 regular cannabis users. Independent Drug Monit Unit 1997
  • Kotin J, Post RM, Goodwin FK. Delta 9-tetrahydrocannabinol in depressed patients. Arch Gen Psychiatry 1973;28:345-8
  • Regelson W, Butler JR, Schulz J, et al. Delta-9-THC as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Bruade MC, Szara S, editors, The pharmacology of marijuana. New York: Raven Press; 1976
  • Gruber AJ, Pope HG Jr, Brown ME. Do patients use marijuana as antidepressant? Depression 1996;4(2):77-80
  • Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005;59(3):291-5
  • Schnelle M, Grotenhermen F, Reif M, et al. Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forsch Komplementarmed 1999;3(Suppl):28-36
  • Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44-8
  • Clark AJ, Ware MA, Yazer E, et al. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004;62(11):2098-100
  • Page SA, Verhoef MJ, Stebbins RA, et al. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 2003;30:201-5
  • Amtmann D, Weydt P, Johnson KL, et al. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2004;21(2):95-104
  • Prentiss D, Power R, Balmas G, et al. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr 2004;35(1):38-45
  • Woolridge E, Barton S, Samuel J, et al. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 2005;29(4):358-67
  • Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr 2007;45(5):545-54
  • Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346(6284):561-4
  • Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001;58(4):322-8
  • Jones RT. Marihuana-induced “high”: influence of expectation, setting and previous drug experience. 1971;23(4):359-69
  • Curran HV, Brignell C, Fletcher S, et al. Cognitive and subjective dose-response effects of acute delta-9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 2002;164:61-70
  • Campbell I. The amotivational syndrome and cannabis use with emphasis on the Canadian scene. Ann NY Acad Sci 1976;282:33-6
  • Musty RE, Kaback L. Relationships between motivation and depression in chronic marijuana users. Life Sci 1995;56:2151-8
  • Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001;158(12):2033-7
  • Patton GC, Coffey C, Carlin JB, et al. Cannabis use and mental health in young people: cohort study. BMJ 2002;325(7374):1195-8
  • Fergusson DM, Horwood LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 2002;97(9):1123-35
  • Arseneault L, Cannon M, Witton J, et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004;184:110-7
  • Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes. Lancet 2007;370(9584):319-28
  • Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 2005;16(5-6):333-a352
  • Serra G, Fratta W. A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemol Ment Health 2007;3:25-36
  • Ehlers CL, Slutske WS, Lind PA, et al. Association between single nucleotide polymorphisms in the cannabinoid receptor gene (CNR1) and impulsivity in southwest California Indians. Twin Res Hum Genet 2007;10(6):805-11
  • Barrero FJ, Ampuero I, Morales B, et al. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics 2005;5(2):135-41
  • Koethe D, Llenos IC, Dulay JR, et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2007;114(8):1055-63
  • Hungund BL, Vinod KY, Kassir SA, et al. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004;9(2):184-90
  • Vinod KY, Arango V, Xie S, et al. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry 2005;57(5):480-6
  • Dean B, Sundram S, Bradbury R, et al. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001;103(1):9-15
  • Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(2):355-60
  • Newell KA, Deng C, Huang XF. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 2006;172(4):556-60
  • Leweke FM, Giuffrida A, Wurster U, et al. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999;10(8):1665-9
  • Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004;29(11):2108-14
  • Ujike H, Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 2004;96(4):376-81
  • Hill MN, Miller GE, Ho WS, et al. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008;41(2):48-53
  • Barbour KA, Blumenthal JA. Exercise training and depression in older adults. Neurobiol Aging 2005;26(Suppl 1):119-23
  • Sparling PB, Giuffrida A, Piomelli D, et al. Exercise activates the endocannabinoid system. Neuroreport 2003;14(17):2209-11
  • Hillard CJ, Hill MN, Carrier EJ, et al. Regulation of cannabinoid receptor expression by chronic, unpredictable stress in rats and mice. Program No. 746.19/W22. 2006 Neuroscience Meeting Planner. 2006. Atlanta, GA: Society for Neuroscience. Available from: http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={E784B249-55A4-4026- [Last accessed 2008 September 7]
  • Bortolato M, Mangieri RA, Fu J, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007;62(10):1103-10
  • Hill MN, Ho WV, Carrier EJ, et al. Differential regulation of the endocannabinoid system following treatment with pharmacologically distinct antidepressants. Program No. 447.4. 2005 Neuroscience Meeting Planner. 2005. San Diego, CA: Society for Neuroscience. Available from: http://sfn.scholarone.com/itin2005/main.html?new_page_id=126&abstract_id=3846&p_num=447.4& [Last accessed 2008 September 7]
  • Hill MN, Carrier EJ, Ho WS, et al. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus. Hippocampus 2008;18(2):221-6
  • Patel S, Roelke CT, Rademacher DJ, et al. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004;45(12):5431-8
  • Patel S, Roelke CT, Rademacher DJ, et al. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 2005;21(4):1057-69
  • Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002;418(6897):530-4
  • Kamprath K, Marsicano G, Tang J, et al. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci 2006;26(25):6677-86
  • Haller J, Bakos N, Szirmay M, et al. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002;16(7):1395-8
  • Martin M, Ledent C, Parmentier M, et al. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002;159(4):379-87
  • Degroot A, Nomikos GG. Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur J Neurosci 2004;20(4):1059-64
  • Barna I, Zelena D, Arszovszki AC, Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 2004;75(24):2959-70
  • Niwatananun W, Myres MJ, Eddwards E. Neuropsychopharmacology and molecular pharmacology of the cannabinoid system in the learned helpless model of depression. In: Pharmaceutical sciences. Baltimore, MD: University of Maryland; 2000
  • Macrì S, Laviola G. Single episode of maternal deprivation and adult depressive profile in mice: interaction with cannabinoid exposure during adolescence. Behav Brain Res 2004;154(1):231-8
  • Bambico FR, Katz N, Debonnel G, et al. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007;27(43):11700-11
  • Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005;115(11):3104-16
  • Rutkowska M, Jachimczuk O. Antidepressant-like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors. Acta Pol Pharm 2004;61(2):165-7
  • Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005;15(6):593-9
  • Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005;102(51):18620-5
  • Hayase T. Chronologically overlapping occurrences of nicotine-induced anxiety and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs. BMC Neurosci 2007;8:76(1-9)
  • Naidu PS, Varvel SA, Ahn K, et al. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology 2007;192(1):61-70
  • Bambico FR, Cassano T, Nguyen NT, et al. Emotional behavior and serotonergic neurotransmission in fatty acid amide hydrolase (FAAH) knock-out mice. Program No. 914.18. 2007 Neuroscience Meeting Planner. 2007. San Diego, CA: Society for Neuroscience; Available from: http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={958CC28E-F4DE-47C8- [Last accessed 2008 September 7]
  • Miczek KA. 9-tetrahydrocannabinol: antiaggressive effects in mice, rats and squirrel monkeys. Science 1978;199(4336):1459-61
  • Rademacher DJ, Hillard CJ. Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(3):633-41
  • Onaivi ES, Ishiguro H, Gong JP, et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 2008;3(2):e1640. Published online 2008 February 20, doi:10.1371/journal.pone.0001640
  • Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005;57(3):261-7
  • Shearman LP, Rosko KM, Fleischer R, et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003;14(8):573-82
  • Tzavara ET, Davis RJ, Perry KW. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003;138(4):544-53
  • Malone DT, Taylor DA. Modulation of Δ9-tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat. Br J Pharmacol 1998;124(7):1419-24
  • Carlini EA, Lindsey CJ. Effect of serotonergic drugs on the aggressiveness induced by delta 9-tetrahydrocannabinol in rem-sleep-deprived rats. Braz J Med Biol Res 1982;15(4-5):281-3
  • Aso E, Renoir T, Ledent C, et al. Lack of CB1 receptor alters serotonin system: an electrophysiological and in vivo microdialysis study [poster P.2.03]. European College of Neuropsychopharmacology Workshop on Neuropsychopharmacology for Young Scientists in Europe; 2008
  • Aso E, Ozaita A, Valdizán EM, et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 2008;105(2):565-72
  • Gobbi G, Murphy DL, Lesch K, et al. Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J Pharmacol Exp Ther 2001;296(3):987-95
  • Maudhuit C, Hamon M, Adrien J. Electrophysiological activity of raphe dorsalis serotoninergic neurones in a possible model of endogenous depression. Neuroreport 1995;6(4):681-4
  • Maldonado R, Rodriguez de Fonseca F. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 2002;22(9):3326-31
  • Solinas M, Justinova Z, Goldberg SR, et al. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 2006;98(2):408-19
  • Pillolla G, Melis M, Perra S, et al. Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo. Psychopharmacology 2007;191(3):843-53
  • Muntoni AL, Pillolla G, Melis M, et al. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. Eur J Neurosci 2006;23:2385-94
  • Mendiguren A, Pineda J. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats. Eur J Pharmacol 2006;534(1-3):83-8
  • Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990;87(5):1932-6
  • Oropeza VC, Page ME, Van Bockstaele EJ. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res 2005;1046(1-2):45-54
  • Oropeza VC, Mackie K, Van Bockstaele EJ. Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 2007;1127(1):36-44
  • Jentsch JD, Andrusiak E, Tran A, et al. Δ9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 1997;16(6):426-32
  • Moranta D, Esteban S, García-Sevilla JA. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 2004;369(5):516-24
  • Schlicker E, Timm J, Zentner J, et al. Cannabinoid CB1 receptormediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1997;356(5):583-9
  • Hill MN, Patel S, Carrier EJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005;30(3):508-15
  • McLaughlin RJ, Hill MN, Morrish AC, et al. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behav Pharmacol 2007;18(5-6):431-8
  • Hattan PR, Bambico FR, Duranti A, et al. Cannabinoids modify hippocampal serotonergic transmission [abstract C-B3058]. 2nd Annual Canadian Neurscience Meeting; 2008; Montreal, Quebec
  • Aguado T, Monory K, Palazuelos J, et al. The endocannabinoid system drives neural progenitor proliferation. FASEB J 2005;19(12):1704-6
  • Aguado T, Romero E, Monory K, et al. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J Biol Chem 2007;282(33):23892-8
  • Jin K, Xie L, Kim SH, et al. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol 2004;66(2):204-8
  • Rueda D, Navarro B, Martinez-Serrano A, et al. The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J Biol Chem 2002;277(48):46645-50
  • Kim SH, Won SJ, Mao XO, et al. Role for neuronal nitric-oxide synthase in cannabinoid-induced neurogenesis. J Pharmacol Exp Ther 2006;319(1):150-4
  • Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370(9600):1706-13
  • Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295(7):761-75
  • Mitchell PB, Morris MJ. Depression and anxiety with rimonabant. Lancet 2007;370(9600):1671-2
  • Steiner MA, Marsicano G, Nestler EJ, et al. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 2008;33(1):54-67
  • Navarro M, Hernández E, Muñoz RM, et al. Acute administration of the CB1 annabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997;8(2):491-6
  • Arevalo C, de Miguel R, Hernández-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 2001;70(1):123-31
  • Haller J, Varga B, Ledent C, et al. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004;15(4):299-304
  • Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 2001;24(5):467-77
  • Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54(10):2838-43
  • Golomb BA. Cholesterol and violence: is there a connection? Ann Intern Med 1998;128(6):478-87
  • Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 2008; published on 2008 February 28, doi:10.1177/0269881107083808
  • Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005;25(4):336-41
  • Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry 2004;56(1):46-53
  • Varvel SA, Wise LE, Niyuhire F, et al. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 2007;32(5):1032-41
  • Egertová M, Cravatt BF, Elphick MR. Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 2003;119(2):481-96
  • Di Marzo V, Capasso R, Matias I, et al. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 2008;153(6):1272-80
  • Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 2008;5(2):e45. Published online 2008 February 26, doi:10.1371/journal.pmed.0050045
  • Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 1990;51(Suppl 14-20)
  • Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 1991;5(4):219-29
  • Béïque J, de Montigny C, Blier P, Debonnel G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology 2000;39(10):1800-12
  • Cooper BR, Wang CM, Cox RF, et al. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 1994;11(2):133-41
  • Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology 2001;155(1):52-7
  • Santarelli L, Gobbi G, Debs PC, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviours and increases serotonergic function. Proc Natl Acad Sci USA 2001;98(4)1912-7
  • Guiard BP, Gardier AM, Blier P. Potentiating antidepressant strategy: focus on NK1 receptor antagonists. Eur Neuropsychopharmacol 2006;1(16 Suppl):S31-2
  • Gobbi G, Cassano T, Radja F, et al. Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. Eur Neuropsychopharmacol 2007;17(5):328-38
  • Blier P, Bouchard C. Effect of repeated electroconvulsive shocks on serotonergic neurons. Eur J Pharmacol 1992;211(3):365-73
  • Dorr AE, Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J Pharmacol Exp Ther 2006;318(2):890-8
  • Szabo ST, de Montigny C, Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2000;3(1):1-11
  • Grant MM, Weiss JM. Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol Psychiatry 2001;49(2):117-29
  • Szabo ST, Blier P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacol 2001;25(6):845-57
  • Haddjeri N, Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol Psychiatry 2001;50(3):191-9
  • Morcuende S, Gadd CA, Peters M, et al. Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur J Neurosci 2003;18(7):1828-36
  • Kochman LJ, dos Santos AA, Fornal CA, Jacobs BL. Despite strong behavioral disruption, Δ9-tetrahydrocannabinol does not affect cell proliferation in the adult mouse dentate gyrus. Brain Res 2006;1113(1):86-93
  • Braida D, Iosuè S, Pegorini S, Sala M. Δ9-Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol 2004;506(1):63-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.